TMO: Strong Q2 growth, AI-driven innovation, and reshoring trends set the stage for robust multi-year expansion
Organic growth and EPS exceeded expectations in Q2, prompting a raised full-year outlook. Pharma and biotech demand is strengthening, with AI and funding cycles fueling growth, while reshoring and M&A drive future opportunities. AI adoption and strong segment performance support confidence in achie…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.